Literature DB >> 11922950

Progress in understanding the structure-activity relationships of P-glycoprotein.

Terry R Stouch1, Olafur Gudmundsson.   

Abstract

Efflux out of cells by P-glycoprotein (P-gp) represents a serious liability for pharmaceuticals, particularly for anti-cancer drugs. Consequently, identification of compounds as potential substrates is important for understanding their bioavailability. Also, the development of agents which reverse this multi-drug resistance phenotype has received considerable attention. Assays for determining these activities are reviewed. Recent literature and studies into the structure-activity relationships (SAR) of the resulting data are discussed. Multiple binding sites and other complicating factors have prevented the development of a truly general, conclusive SAR either for substrate or inhibitory activities. Consequently, many models have tended to address only very general properties, such as lipophilicity and size. However, progress has been made in the last few years toward more specific SAR suggesting well-defined structural features responsible for both activities. The future of understanding the details of P-gp SAR lies in more specific assays that target specific binding sites and mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11922950     DOI: 10.1016/s0169-409x(02)00006-6

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  20 in total

Review 1.  Pharmacophore-based discovery of ligands for drug transporters.

Authors:  Cheng Chang; Sean Ekins; Praveen Bahadduri; Peter W Swaan
Journal:  Adv Drug Deliv Rev       Date:  2006-09-26       Impact factor: 15.470

Review 2.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

Review 3.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.

Authors:  Wolfgang Löscher; Heidrun Potschka
Journal:  NeuroRx       Date:  2005-01

4.  QSAR modeling of the blood-brain barrier permeability for diverse organic compounds.

Authors:  Liying Zhang; Hao Zhu; Tudor I Oprea; Alexander Golbraikh; Alexander Tropsha
Journal:  Pharm Res       Date:  2008-06-14       Impact factor: 4.200

5.  Experimental and computational studies of epithelial transport of mefenamic acid ester prodrugs.

Authors:  Kamonthip Wiwattanawongsa; Vimon Tantishaiyakul; Luelak Lomlim; Yon Rojanasakul; Sirirat Pinsuwan; Sanae Keawnopparat
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

Review 6.  Molecular Modeling of Drug-Transporter Interactions-An International Transporter Consortium Perspective.

Authors:  Avner Schlessinger; Matthew A Welch; Herman van Vlijmen; Ken Korzekwa; Peter W Swaan; Pär Matsson
Journal:  Clin Pharmacol Ther       Date:  2018-08-30       Impact factor: 6.875

Review 7.  Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target.

Authors:  Anand Balakrishnan; James E Polli
Journal:  Mol Pharm       Date:  2006 May-Jun       Impact factor: 4.939

8.  Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages.

Authors:  Cristina Seral; Jean-Michel Michot; Hugues Chanteux; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

Review 9.  Advancement of structure-activity relationship of multidrug resistance-associated protein 2 interactions.

Authors:  Li Xing; Yiding Hu; Yurong Lai
Journal:  AAPS J       Date:  2009-06-03       Impact factor: 4.009

10.  Clinical significance of ABCB1 genotyping in oncology.

Authors:  Alma Hamidovic; Kristine Hahn; Jill Kolesar
Journal:  J Oncol Pharm Pract       Date:  2009-04-28       Impact factor: 1.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.